NZ743049A - Anti-cd3-folate conjugates and their uses - Google Patents

Anti-cd3-folate conjugates and their uses

Info

Publication number
NZ743049A
NZ743049A NZ743049A NZ74304916A NZ743049A NZ 743049 A NZ743049 A NZ 743049A NZ 743049 A NZ743049 A NZ 743049A NZ 74304916 A NZ74304916 A NZ 74304916A NZ 743049 A NZ743049 A NZ 743049A
Authority
NZ
New Zealand
Prior art keywords
folate conjugates
folate
conjugates
conjugate
diseases
Prior art date
Application number
NZ743049A
Other languages
English (en)
Inventor
Harun Rashid
Feng Tian
Marco Gymnopoulos
Original Assignee
Ambrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambrx Inc filed Critical Ambrx Inc
Publication of NZ743049A publication Critical patent/NZ743049A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ743049A 2015-11-03 2016-11-02 Anti-cd3-folate conjugates and their uses NZ743049A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562250451P 2015-11-03 2015-11-03
US201562267086P 2015-12-14 2015-12-14
US201662374693P 2016-08-12 2016-08-12
PCT/US2016/060087 WO2017079272A2 (en) 2015-11-03 2016-11-02 Anti-cd3-folate conjugates and their uses

Publications (1)

Publication Number Publication Date
NZ743049A true NZ743049A (en) 2025-08-29

Family

ID=58662682

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ743049A NZ743049A (en) 2015-11-03 2016-11-02 Anti-cd3-folate conjugates and their uses

Country Status (13)

Country Link
US (2) US11851488B2 (enExample)
EP (1) EP3370771A4 (enExample)
JP (2) JP6931649B2 (enExample)
KR (1) KR20180077271A (enExample)
CN (1) CN108348603B (enExample)
AU (1) AU2016349786C1 (enExample)
BR (1) BR112018009004A8 (enExample)
CA (1) CA3002573A1 (enExample)
IL (1) IL258759B2 (enExample)
MX (1) MX2018005232A (enExample)
NZ (1) NZ743049A (enExample)
SG (2) SG10201913746RA (enExample)
WO (1) WO2017079272A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021503899A (ja) * 2017-11-22 2021-02-15 ジェルター， インコーポレイテッド コラーゲンを操作するための方法およびシステム
KR20210063351A (ko) * 2018-08-28 2021-06-01 암브룩스, 인코포레이티드 항-cd3 항체 폴레이트 생체접합체 및 이들의 용도
KR102239781B1 (ko) * 2019-04-08 2021-04-13 주식회사 녹십자 Gpnmb 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도
US20200392230A1 (en) * 2019-05-14 2020-12-17 Qlb Biotherapeutics Bispecific anti-cd3 x cd20 antibodies and uses thereof
CN120775051A (zh) 2019-05-21 2025-10-14 诺华股份有限公司 Cd19结合分子及其用途
TWI888487B (zh) * 2020-02-14 2025-07-01 日商協和麒麟股份有限公司 與ｃｄ３結合之雙特異性抗體
TWI827807B (zh) * 2020-02-26 2024-01-01 香港商潤俊（中國）有限公司 抗cd3抗體葉酸生物共軛物及其用途
WO2021173889A1 (en) 2020-02-26 2021-09-02 Ambrx, Inc. Uses of anti-cd3 antibody folate bioconjugates
CN116157416A (zh) 2020-08-25 2023-05-23 吉利德科学公司 靶向hiv的多特异性抗原结合分子及其使用方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
DE3377484D1 (en) 1982-04-19 1988-09-01 Nissan Motor Method for controlling reduction ratio of continuously variable transmission with acceleration compensation
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
EP0188256B1 (en) 1985-01-14 1991-08-21 NeoRx Metal radionuclide labeled proteins for diagnosis and therapy
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
DK0615451T3 (da) 1992-05-26 2006-04-24 Immunex Corp Hidtil ukendt cytokin der binder til CD30
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
ES2297889T3 (es) 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
CA2348822A1 (en) 1998-10-30 2000-05-11 Novozymes A/S Glycosylated proteins having reduced allergenicity
CA2487424C (en) 2002-05-30 2011-01-04 The Scripps Research Institute Copper-catalysed ligation of azides and acetylenes
EP1613735B1 (en) 2003-04-17 2012-01-25 The Scripps Research Institute Expanding the eukaryotic genetic code
CN102618605B (zh) 2003-06-18 2015-09-02 斯克利普斯研究院 非天然活性氨基酸遗传密码增加
GB0716160D0 (en) 2007-08-17 2007-09-26 Biotransformations Ltd Materials and methods for treating cancers which express folate receptors
JP2012034668A (ja) 2010-08-12 2012-02-23 Tohoku Univ ヒト型化抗ｅｇｆｒ抗体リジン置換可変領域断片及びその利用
JP6400470B2 (ja) * 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
SMT201900239T1 (it) * 2011-05-21 2019-05-10 Macrogenics Inc Molecole di legame a cd3 in grado di legare cd3 umano e non umano
US9718893B2 (en) * 2011-12-19 2017-08-01 Synimmune Gmbh Bispecific antibody molecule
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
JP2016531100A (ja) 2013-07-12 2016-10-06 ザイムワークス，インコーポレイテッド 二重特異的なｃｄ３及びｃｄ１９抗原結合構築物
EP2840091A1 (en) * 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
EP3172235A2 (en) * 2014-07-25 2017-05-31 Cytomx Therapeutics Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
JP2018534933A (ja) * 2015-11-02 2018-11-29 ヤンセン ファーマシューティカ エヌ．ベー． 抗ｉｌ１ｒａｐ抗体、ｉｌ１ｒａｐとｃｄ３を結合する二重特異性抗原結合分子、及びその使用
US20210179734A1 (en) * 2018-04-17 2021-06-17 Invenra Inc. Trivalent trispecific antibody constructs
KR20210063351A (ko) * 2018-08-28 2021-06-01 암브룩스, 인코포레이티드 항-cd3 항체 폴레이트 생체접합체 및 이들의 용도
MX2021009644A (es) * 2019-02-12 2021-09-08 Ambrx Inc Composiciones que contienen, metodos y usos de conjugados de anticuerpo-agonista de tlr.
CN116178547A (zh) * 2019-02-22 2023-05-30 武汉友芝友生物制药股份有限公司 Cd3抗原结合片段及其应用

Also Published As

Publication number Publication date
US11851488B2 (en) 2023-12-26
JP2018535972A (ja) 2018-12-06
IL258759A (en) 2018-06-28
AU2016349786A1 (en) 2018-06-21
CA3002573A1 (en) 2017-05-11
CN108348603B (zh) 2023-12-29
IL258759B2 (en) 2023-04-01
KR20180077271A (ko) 2018-07-06
IL258759B (en) 2022-12-01
JP7220755B2 (ja) 2023-02-10
CN108348603A (zh) 2018-07-31
BR112018009004A8 (pt) 2019-02-26
US20180319885A1 (en) 2018-11-08
BR112018009004A2 (pt) 2018-10-30
AU2016349786C1 (en) 2024-11-07
SG11201803211TA (en) 2018-05-30
AU2016349786B2 (en) 2023-11-16
US20240239889A1 (en) 2024-07-18
JP2021181487A (ja) 2021-11-25
MX2018005232A (es) 2018-08-15
WO2017079272A2 (en) 2017-05-11
SG10201913746RA (en) 2020-03-30
EP3370771A2 (en) 2018-09-12
JP6931649B2 (ja) 2021-09-08
EP3370771A4 (en) 2019-06-19
WO2017079272A9 (en) 2017-08-03

Similar Documents

Publication Publication Date Title
NZ743049A (en) Anti-cd3-folate conjugates and their uses
CY1124131T1 (el) Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
PH12019500923A1 (en) Anti-pd-1 antibodies and compositions
MX2022013524A (es) Anticuerpos neutralizantes para el virus de inmunodeficiencia humana.
SA517381167B1 (ar) عامل علاجي مستحث للسمية الخلوية
MX2022001105A (es) Anticuerpos anti tigit.
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
TN2015000396A1 (en) Antibody drug conjugates
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
MX2018003936A (es) Anticuerpos anti proteina de muerte celular programada 1 (pd-1) y composiciones.
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
TN2016000472A1 (en) Igf-1r antibody-drug-conjugate and its use for the treatment of cancer.
MX2018015272A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
PH12020550964A1 (en) Heavy chain antibodies binding to cd22
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
MX2018015268A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
MX2018015274A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
MX2020002802A (es) Anticuerpos de cadena pesada que se unen a ectoenzimas.
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
HK1238261A1 (en) Novel anti-mfi2 antibodies and methods of use
HK1234311A1 (en) Novel anti-rnf43 antibodies and methods of use